Business ❯ Pharmaceuticals ❯ Drug Development

Licensing Agreements

Zaltenibart Chronic Obstructive Pulmonary Disease (COPD) BioNTech Epilepsy Treatment International Licensing Clinical Trials Obesity Treatments Glenmark Pharmaceuticals Immune-mediated Diseases Multiple Sclerosis

Novo Nordisk Licenses Chinese Oral GLP‑1/GIP Obesity Pill for Up to $2.6 Billion

The deal gives Novo global development rights outside Greater China and signals a push to rebuild its weight‑loss pill pipeline.

Nanexa Licenses PharmaShell to Novo Nordisk in Deal Worth Up to €1.17 Billion

SK Biopharmaceuticals Licenses Biohaven’s Opakalim in Deal Worth Up to $795 Million

Hanmi Licenses HM17321 to Genentech in $190 Million Upfront Deal Valued at $2.3 Billion

Lilly Secures Global Rights to Hanmi’s Sonefpeglutide

JW Pharmaceutical Licenses Korean Rights to Gan & Lee’s GLP-1 Drug in Deal Worth Up to $81 Million

Lupin Strikes Semaglutide Licensing Deal With Galenicum Covering 23 Countries

Crescent, Kelun-Biotech Trade Cancer Asset Rights in Cross-Border Deal as Crescent Secures $185 Million

Novo Nordisk Licenses Omeros’ MASP-3 Drug in Deal Worth Up to $2.1 Billion

Zenas BioPharma Licenses InnoCare’s Orelabrutinib in Autoimmune Deal Topping $2 Billion

Glenmark Strikes Exclusive Deal With Hengrui for Next‑Gen HER2 ADC, Paying $18 Million Upfront

GSK Closes $12 Billion Licensing Pact for Hengrui’s COPD Therapy and 11 Preclinical Assets

Glenmark Stock Hits Record High on $700 Million AbbVie Cancer Drug Deal

Bristol Myers Squibb and BioNTech partner on $11 billion bispecific antibody cancer drug